Table 1.

Monthly Formulary Price for Orally Administered Chemotherapy Offered by Medicare Part D Formularies in 2014 and Median Duration of Drug Use

Drug	Median Monthly Price ($)	25th Percentile of Monthly Price ($)	75th Percentile of Monthly Price ($)	Median Duration of Use (months)
Abiraterone	7,009	6,956	7,089	8
Afatinib	6,279	6,211	6,319	11
Axitinib	10,057	9,920	10,183	7
Cabozantinib	10,888	10,770	10,960	7
Crizotinib	11,908	11,816	12,016	8
Dabrafenib	8,359	8,269	8,414	5
Dasatinib	9,516	9,413	9,633	12
Enzalutamide	8,128	8,046	8,132	9
Erlotinib	6,353	6,313	6,417	11
Everolimus	9,976	9,877	10,034	5
Imatinib	7,832	7,764	7,898	12
Lapatinib	5,123	5,073	5,176	9
Lenalidomide	13,683	13,537	13,779	4
Nilotinib	9,543	9,480	9,655	12
Pazopanib	7,924	7,843	7,904	8
Pomalidomide	16,093	15,923	16,202	8
Regorafenib	15,206	15,020	15,213	3
Sorafenib	10,811	10,728	10,937	6
Sunitinib	13,003	12,919	13,170	12
Trametinib	9,564	9,466	9,632	5
Vandetanib	11,421	11,304	11,502	12
Vemurafenib	11,241	11,071	11,355	5
Vorinostat	11,469	11,312	11,609	4

NOTE. Prices are from the Prescription Drug Plan Formulary, Pharmacy Network, and Pricing Information Files available through the Centers for Medicare & Medicaid Services and represent the plan level average monthly reimbursement (amount paid from all sources [patient, plan, and Medicare]) for formulary Part D drugs for a 30-day supply of the most commonly covered dose of each drug selected. Median costs were calculated across all plans, and interquartile ranges are indicated. Median duration of use was obtained from data provided in Howard et al.¹⁵ For products not included in Howard et al, we used the drug product label to identify median duration of therapy (Data Supplement).